L-N^δ-(tert-butoxycarbonyl)-ornithine tert-butyl ester | 910630-87-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-N^δ-(tert-butoxycarbonyl)-ornithine tert-butyl ester
• 英文别名: (S)-tert-butyl 2-amino-5-(tert-butoxycarbonylamino)pentanoate；tert-butyl (2S)-2-amino-5-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate
• CAS: 910630-87-4
• 化学式: C₁₄H₂₈N₂O₄
• 分子量: 288.387
• InChiKey: GTAZURHJLPRGJL-JTQLQIEISA-N

物化性质

• 沸点：
  383.5±32.0 °C(Predicted)
• 密度：
  1.031±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  20
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  90.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  L-N^δ-(tert-butoxycarbonyl)-ornithine tert-butyl ester 、 (17R,18S,19S,20S,21S,22S)-18,19,20,21,22-Pentakis-benzyloxy-25-((S)-1-tert-butoxycarbonyl-2-methyl-propylcarbamoyl)-17-hydroxy-pentacos-14-ynoic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以83%的产率得到(S)-5-tert-Butoxycarbonylamino-2-[(17R,18S,19S,20S,21S,22S)-18,19,20,21,22-pentakis-benzyloxy-25-((S)-1-tert-butoxycarbonyl-2-methyl-propylcarbamoyl)-17-hydroxy-pentacos-14-ynoylamino]-pentanoic acid tert-butyl ester
  参考文献：
  名称：

  Stereochemistry of Sagittamide A:  Prediction and Confirmation

  摘要：

  The C5-C10 relative stereochemistry of sagittamide A was predicted, with the use of the (3)J(H,H) profiles assembled from the spin-coupling constants reported in the literature. The predicted relative stereochemistry was then confirmed by a total synthesis of two relevant remote diastereomers. The absolute configuration of sagittamide A was established through a detailed H-1 NMR analysis of the two remote diastereomers, followed by doping experiments of them with the authentic natural product.

  DOI：

  10.1021/ol061582d
• 作为产物：
  描述：

  N-苄氧羰基-N’-叔丁氧羰基-L-鸟氨酸 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 、 二氯甲烷 、 叔丁醇 为溶剂， 反应 24.0h， 生成 L-N^δ-(tert-butoxycarbonyl)-ornithine tert-butyl ester
  参考文献：
  名称：

  Stereochemistry of Sagittamide A:  Prediction and Confirmation

  摘要：

  The C5-C10 relative stereochemistry of sagittamide A was predicted, with the use of the (3)J(H,H) profiles assembled from the spin-coupling constants reported in the literature. The predicted relative stereochemistry was then confirmed by a total synthesis of two relevant remote diastereomers. The absolute configuration of sagittamide A was established through a detailed H-1 NMR analysis of the two remote diastereomers, followed by doping experiments of them with the authentic natural product.

  DOI：

  10.1021/ol061582d

文献信息

• TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY
  申请人：Bollu Venkataiah

  公开号：US20120040985A1

  公开（公告）日：2012-02-16

  The present invention comprises TGR5 agonists of structural formula I, wherein X, R 1 , R 2 , and R 5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprises composition comprising the compounds, N-oxides, and/or pharmaceutically acceptable salts thereof. The invention also comprises use of the compounds and compositions for treating diseases in which TGR5 is a mediator or is implicated. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases in which TGR5 is a mediator or is implicated.

  本发明涉及结构式I的TGR5激动剂，其中X、R1、R2和R5如本文所定义，以及它们的N-氧化物和药学上可接受的盐。本发明还包括包含这些化合物、N-氧化物和/或药学上可接受的盐的组合物。本发明还包括使用这些化合物和组合物治疗TGR5是介质或被牵涉的疾病。本发明还包括使用这些化合物制造药物，特别是用于治疗TGR5是介质或被牵涉的疾病。
• Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity
  申请人：Bollu Venkataiah

  公开号：US08785488B2

  公开（公告）日：2014-07-22

  The present invention comprises TGR5 agonists of structural formula I, wherein X, R1, R2, and R5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprises composition comprising the compounds, N-oxides, and/or pharmaceutically acceptable salts thereof. The invention also comprises use of the compounds and compositions for treating diseases in which TGR5 is a mediator or is implicated. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases in which TGR5 is a mediator or is implicated.

  本发明包括结构式I的TGR5激动剂，其中X、R1、R2和R5在此定义，以及其N-氧化物和药学上可接受的盐。本发明还包括包含这些化合物、N-氧化物和/或药学上可接受的盐的组合物。本发明还包括使用这些化合物和组合物治疗TGR5是介质或涉及的疾病的用途。本发明还包括使用这些化合物制造药品，特别是用于治疗TGR5是介质或涉及的疾病。
• US8785488B2
  申请人：——

  公开号：US8785488B2

  公开（公告）日：2014-07-22
• Stereochemistry of Sagittamide A:  Prediction and Confirmation
  作者：Hirofumi Seike、Indranath Ghosh、Yoshito Kishi

  DOI：10.1021/ol061582d

  日期：2006.8.1

  The C5-C10 relative stereochemistry of sagittamide A was predicted, with the use of the (3)J(H,H) profiles assembled from the spin-coupling constants reported in the literature. The predicted relative stereochemistry was then confirmed by a total synthesis of two relevant remote diastereomers. The absolute configuration of sagittamide A was established through a detailed H-1 NMR analysis of the two remote diastereomers, followed by doping experiments of them with the authentic natural product.